Biotech billionaire Philip Frost agrees to proposed judgment in SEC case [CNBC]
Opko Health, Inc. (OPK)
Last opko health, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.opko.com
Company Research
Source: CNBC
John Parra | Getty Images Phillip Frost attends the Phillip And Patricia Frost Museum of Science Opening and Dedication Ceremony at Frost Art Museum at Frost Art Museum on May 8, 2017 in Miami, Florida. Dr. Philip Frost, a biotech billionaire and the former chairman of Teva , agreed to a proposed settlement with the Securities and Exchange Commission on a civil case that the agency called lucrative market manipulation schemes worth $27 million, according to a news release . In the proposed settlement, filed Thursday, Frost did not admit or deny the SEC's allegations. Frost is currently the CEO and chairman of Opko Health . As part of the proposed settlement, which is subject to court approval, Frost will pay $5.5 million to the SEC and is permanently barred from participating in offerings of penny stocks, with exceptions, according to court documents. Frost, Opko Health, and Frost Gamma Investments Trust, of which Frost is the trustee,
Show less
Read more
Impact Snapshot
Event Time:
OPK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPK alerts
High impacting Opko Health, Inc. news events
Weekly update
A roundup of the hottest topics
OPK
News
- GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset [Yahoo! Finance]Yahoo! Finance
- GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024 [Yahoo! Finance]Yahoo! Finance
- OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
- OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp [Yahoo! Finance]Yahoo! Finance
- OPKO Health, Inc. (NASDAQ: OPK) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $1.50 price target on the stock.MarketBeat
OPK
Earnings
- 2/27/24 - In-Line
OPK
Sec Filings
- 3/29/24 - Form 4
- 3/29/24 - Form 4
- 3/29/24 - Form 4
- OPK's page on the SEC website